Top Story
Carl Zeiss Meditec (XTRA:AFX) is rolling out its CT LUCIA 621P monofocal intraocular lens in Japan, widening its Cataract Workflow just ahead of a major ophthalmology congress in Kyoto. The CT LUCIA 621P launch in Japan comes at a time when Carl Zeiss Meditec’s share price has shown short-term momentum, with a 1 month share price return of 15.84% and a 90 day share price return of 27.84%. However, longer term total shareholder returns remain weak, with the 1 year total shareholder return down 20.76% and the 5 year total shareholder return down 78.41%.
This indicates that recent optimism is still set against a substantial longer term drawdown. Spot opportunities around Carl Zeiss Meditec by comparing its recent rebound and long slide with a hand picked 193 high quality undervalued stocks that also pair solid fundamentals with compressed expectations. Carl Zeiss Meditec has surged in the past quarter after years of heavy damage to long term holders.
Is this rebound just a relief rally, or is the valuation still pricing in too much gloom? Most Popular Narrative: 32% Overvalued Carl Zeiss Meditec last closed at €35.54, while the most followed narrative estimates fair value at €26.89 using a 6.0% discount rate. That gap frames the recent rebound as a potential overshoot rather than a clean reset.
The current valuation implies investors are paying a premium despite group revenue declining 2.2% to €1.554b and adjusted EBITA margin standing at 8.0% for the first nine months of FY25/26, so the stock reflects high expectations for margin recovery. See why 33 investors see Carl Zeiss Meditec as 32% overvalued . Result: Fair Value of €26.89 (OVERVALUED) Still, if the ProfitUp program lifts margins well above the current 8.0% level, or if China refractive volumes surprise on the upside, the overvaluation case weakens fast.
Find out about the key risks to this Carl Zeiss Meditec narrative . Another View: Carl Zeiss Meditec Through Its P/E Ratio The DCF narrative paints Carl Zeiss Meditec as 32% overvalued, yet the P/E picture is more forgiving. At 25.6x earnings, the shares are cheaper than the wider European medical equipment group on 28x and below a fair ratio of 28.8x.
Is the market over-penalising past setbacks? See what the numbers say about this price in our valuation breakdown, then decide which lens you trust most: the narrative fair value or the earnings multiple, as you weigh up risk and potential reward for AFX. See what the numbers say about this price — find out in our valuation breakdown.
XTRA:AFX P/E Ratio as at Oct 2026 Next Steps Sentiment around Carl Zeiss Meditec is split, with past damage and fresh optimism pulling in opposite directions. Move quickly and stress test the story against hard numbers. To weigh that balance for yourself, start with a clear view of both sides through 2 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Carl Zeiss Meditec? If Carl Zeiss Meditec has your attention, do not stop there. Cast the net wider and pressure test your next moves across sectors and styles.
Target dependable cash generators and stress test your income plan with a curated 227 dividend fortresses that focus on payouts backed by stronger financial profiles. Hunt for mispriced quality by scanning a focused 612 high quality undiscovered gems that combine solid fundamentals with limited market attention. Protect the downside of your portfolio by filtering through a 219 resilient stocks with low risk scores that concentrates on sturdier balance sheets and calmer return profiles.
New: AI Stock Screener & Alerts Our new AI Stock Screener scans the market every day to uncover opportunities. • Dividend Powerhouses (3%+ Yield) • Undervalued Small Caps with Insider Buying • High growth Tech and AI Companies Or build your own from over 50 metrics. Explore Now for Free Have feedback on this article? Concerned about the content?
Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Source: Simply Wall Street
